165547-79-5Relevant articles and documents
Medicine composition for treating myocardial damage and preparation method and use thereof
-
Paragraph 0023; 0025; 0026; 0027; 0028, (2018/09/26)
The invention discloses a medical composition for treating myocardial damage, and belongs to the technical field of medicines. The medical composition comprises active components having the structureas shown in the description, one or more of a pharmaceutic adjuvant, a diluent or a carrier. The invention further relates to a preparation method and application of the medical composition. The medical composition has the effect of protecting cardiac muscle cell structures and functions, in addition, can also alleviate ischemia reperfusion injury, is notable in effect, and can be used as a medicine used by patients suffering from myocardium damage.
INHIBITORS OF HIF PROLYL HYDROXYLASE
-
Page/Page column 108, (2016/04/20)
The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
Process Development and Multikilogram-Scale Synthesis of a TRPV1 Antagonist
Cleator, Ed,Scott, Jeremy P.,Avalle, Paulo,Bio, Matthew M.,Brewer, Sarah E.,Davies, Antony J.,Gibb, Andrew D.,Sheen, Faye J.,Stewart, Gavin W.,Wallace, Debra J.,Wilson., Robert D.
, p. 1561 - 1567 (2014/01/06)
The process development and multikilogram preparation of a TRPV1 antagonist, 1, is described. Pyrido[2,3-b]pyrazine 1 was prepared in a convergent manner by the coupling of two key fragments, glyoxal 2 and diamine 3. Glyoxal 2 was synthesized in six chemical steps in 20% overall yield, the key step being a challenging Grignard reaction to install the glyoxalate moiety. Diamine 3 was also prepared in six chemical steps in 46% overall yield, exploiting a regioselective nucleophilic aromatic substitution to obtain the key nitrodiamine intermediate 19.
